Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto disclosure of genetically modified crops used in the production of California food products. Monsanto spent $8.1 million opposing passage, making it the largest contributor against the initiative. The proposition was rejected by a 53.7% majority. Labeling is not required in the US. In 2009 Michael R. Taylor, food safety expert and former Monsanto VP for Public Policy became a Senior Advisor to the FDA Commissioner. Monsanto is a member of the Washington D.C based Biotechnology Industry Organization (BIO), the world's largest biotechnology trade association, which provides "advocacy, business development, and communications services." Between 2010 and 2011 BIO spent a total